News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rhode Island Biotechnology Company EpiVax, Inc. Receives $ 368K Federal Grant to Reengineer Botulinum Toxin Using ''Immunoinformatics''



2/28/2007 12:13:32 PM

PROVIDENCE, R.I.--(BUSINESS WIRE)--EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has received a grant to reengineer botulinum toxin, a protein that is used for cosmetic purposes (the most commonly used brand is known as “Botox”) and which is also used as a revolutionary therapeutic for movement disorders categorized as “dystonias” such as Parkinson’s Disease and Cerebral Palsy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES